Conventional versus modified delivery system technique in commissural alignment from the Evolut low-risk CT substudy.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
02 2022
Historique:
revised: 03 09 2021
received: 23 08 2021
accepted: 29 09 2021
pubmed: 10 10 2021
medline: 8 4 2022
entrez: 9 10 2021
Statut: ppublish

Résumé

We assessed the impact of conventional delivery system (DS) insertion technique on "Hat-marker" orientation/commissural alignment in patients who underwent transcatheter aortic valve replacement (TAVR) in the Evolut Low Risk Trial CT substudy versus a modified technique. Unlike surgical aortic valve replacement, where alignment of the surgical valve commissures with native commissures can be achieved virtually 100% of the time, commissural alignment during TAVR is not achieved consistently. This may subsequently impact the feasibility of both coronary access and reintervention after TAVR. "Hat-marker" orientations during deployment were characterized as outer curve (OC), center front (CF), inner curve, and center back. Severe commissure-to-CA overlap was 0-20°. "Hat-marker" orientations and CA overlap were compared to 240 patients from a single center using the modified 3-o'clock flush port DS technique. In the CT substudy in which conventional DS insertion was performed (flush port at 12 o'clock); 154/249 had both analyzable CT and procedural fluoroscopy to validate "Hat-marker" to C-tab/commissural orientation. On post-TAVR CT, Evolut valve commissural orientation and coronary artery (CA) ostia were identified. Compared to conventional DS technique in the CT substudy, the modified technique had higher rates of "Hat-marker" at OC/CF orientation, improved commissural alignment and reduced severe CA overlap; (left main, 14.2 vs. 27.9%; right coronary artery, 11.7 vs. 27.3% both, 5.0 vs. 13.6%; 1 or both CA, 20.8 vs. 41.6%, all p < 0.01). The modified technique improved initial "Hat-marker" orientation during Evolut deployment and resulted in better commissural alignment and reduced CA overlap.

Sections du résumé

OBJECTIVES
We assessed the impact of conventional delivery system (DS) insertion technique on "Hat-marker" orientation/commissural alignment in patients who underwent transcatheter aortic valve replacement (TAVR) in the Evolut Low Risk Trial CT substudy versus a modified technique.
BACKGROUND
Unlike surgical aortic valve replacement, where alignment of the surgical valve commissures with native commissures can be achieved virtually 100% of the time, commissural alignment during TAVR is not achieved consistently. This may subsequently impact the feasibility of both coronary access and reintervention after TAVR.
METHODS
"Hat-marker" orientations during deployment were characterized as outer curve (OC), center front (CF), inner curve, and center back. Severe commissure-to-CA overlap was 0-20°. "Hat-marker" orientations and CA overlap were compared to 240 patients from a single center using the modified 3-o'clock flush port DS technique.
RESULTS
In the CT substudy in which conventional DS insertion was performed (flush port at 12 o'clock); 154/249 had both analyzable CT and procedural fluoroscopy to validate "Hat-marker" to C-tab/commissural orientation. On post-TAVR CT, Evolut valve commissural orientation and coronary artery (CA) ostia were identified. Compared to conventional DS technique in the CT substudy, the modified technique had higher rates of "Hat-marker" at OC/CF orientation, improved commissural alignment and reduced severe CA overlap; (left main, 14.2 vs. 27.9%; right coronary artery, 11.7 vs. 27.3% both, 5.0 vs. 13.6%; 1 or both CA, 20.8 vs. 41.6%, all p < 0.01).
CONCLUSIONS
The modified technique improved initial "Hat-marker" orientation during Evolut deployment and resulted in better commissural alignment and reduced CA overlap.

Identifiants

pubmed: 34626449
doi: 10.1002/ccd.29973
doi:

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

924-931

Subventions

Organisme : Medtronic funded the Evolut Low Risk Trial

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Fuchs A, Kofoed KF, Yoon SH, et al. Commissural alignment of bioprosthetic aortic valve and native aortic valve following surgical and transcatheter aortic valve replacement and its impact on valvular function and coronary filling. J Am Coll Cardiol Intv. 2018;11:1733-1743.
Tang GHL, Zaid S, Ahmad H, Undemir C, Lansman SL. Transcatheter valve neo-commissural overlap with coronary orifices after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2018;11:e007263.
Buzzatti N, Romano V, De Backer O, et al. Coronary access after repeated transcatheter aortic valve implantation: a glimpse into the future. JACC Cardiovasc Imaging. 2020;13:508-515.
Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:1360-1378.
Abdelghani M, Landt M, Traboulsi H, Becker B, Richardt G. Coronary access after TAVR with a self-expanding bioprosthesis: insights from computed tomography. J Am Coll Cardiol Intv. 2020;13:709-722.
Ochiai T, Chakravarty T, Yoon SH, et al. Coronary access after TAVR. J Am Coll Cardiol Intv. 2020;13:693-705.
Rogers T, Greenspun BC, Weissman G, et al. Feasibility of coronary access and aortic valve reintervention in low-risk TAVR patients. J Am Coll Cardiol Intv. 2020;13:726-735.
Tang GHL, Zaid S, Gupta E, et al. Impact of initial Evolut transcatheter aortic valve replacement deployment orientation on final valve orientation and coronary reaccess. Circ Cardiovasc Interv. 2019;12:e008044.
Khan JM, Bruce CG, Babaliaros VC, Greenbaum AB, Rogers T, Lederman RJ. TAVR roulette: caution regarding BASILICA laceration for TAVR-in-TAVR. J Am Coll Cardiol Intv. 2020;13:787-789.
Tang GHL, Zaid S, Fuchs A, et al. Alignment of transcatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orientation and coronary artery overlap. J Am Coll Cardiol Intv. 2020;13:1030-1042.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Blanke P, Leipsic JA, Popma JJ, et al. Evolut low risk LTISI. Bioprosthetic aortic valve leaflet thickening in the Evolut low risk sub-study. J Am Coll Cardiol. 2020;75:2430-2442.
Lederman RJ, Babaliaros VC, Rogers T, et al. Preventing coronary obstruction during transcatheter aortic valve replacement: from computed tomography to BASILICA. J Am Coll Cardiol Intv. 2019;12:1197-1216.
Tang GHL, Kaneko T, Cavalcante JL. Predicting the feasibility of post-TAVR coronary access and redo TAVR: more unknowns than knowns. J Am Coll Cardiol Intv. 2020;13:736-738.

Auteurs

Gilbert H L Tang (GHL)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Aditya Sengupta (A)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Sophia L Alexis (SL)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Syed Zaid (S)

Division of Cardiology, Westchester Medical Center, Valhalla, New York, USA.

Jonathan A Leipsic (JA)

Center for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Philipp Blanke (P)

Center for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Kendra J Grubb (KJ)

Department of Cardiothoracic Surgery, Emory University, Atlanta, Georgia, USA.

Hemal Gada (H)

Department of Interventional Cardiology, University of Pittsburgh Medical Center Pinnacle, Harrisburg, Pennsylvania, USA.

Steven J Yakubov (SJ)

Department of Interventional Cardiology, OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA.

Toby Rogers (T)

Medstar Heart and Vascular Institute, Washington, District of Columbia, USA.

Stamatios Lerakis (S)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Sahil Khera (S)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

David H Adams (DH)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Samin K Sharma (SK)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Annapoorna Kini (A)

Department of Cardiovascular Surgery and Cardiology, Mount Sinai Hospital, New York, New York, USA.

Michael J Reardon (MJ)

Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH